Attempts to treat extensive disease with topical agents are often met with failure, can add cost, and lead to frustration in the patient-clinician relationship. Biologic agents used in the treatment of psoriasis include the anti-TNF agents adalimumab, etanercept, and infliximab, the anti-interleukin (IL)-12/23 antibody ustekinumab, and the anti-IL-17 antibody secukinumab. Biologics are protein-based drugs derived from living cells. Several biologics have been approved for psoriasis treatment in the past decade, including:. While biologic agents have improved treatment outcomes, they are not effective in all individuals with psoriasis. The combination of biologic agents with traditional therapies may provide improved therapeutic options for patients who inadequately respond to a single drug or when efficacy may be increased with supplementation of another treatment.
The investigators also examined the effect of treatment with biological vs no biological agents on vascular and LV function in psoriasis. It is crucial to understand the immunopathogenesis of psoriasis and the mechanisms of these novel agents in order to to treat the psoriatic population effectively and mitigate disease burden. Biological therapy refers to the use of medication that is tailored to specifically target an immune or genetic mediator of disease. It is also used in the treatment of psoriasis and ankylosing spondylitis. Other biological therapy agents and monoclonal antibodies have not showed as much efficacy in the treatment of IBD.